Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Denenicokin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1-Arm A: BMS-982470 (weekly x 4) + BMS-936558 | EXPERIMENTAL | Dose Escalation BMS-982470 10, 30, 50, 75 or 100 µg/kg Solution, Intravenous, During each 6 week cycle: weekly x 4 (i.e during weeks 1 through 4), Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years |
| Part 1-Arm B: BMS-982470 (3 times/week) + BMS-936558 | EXPERIMENTAL | Dose Escalation BMS-982470 10, 30, 50, 75 or 100 µg/kg Solution, Intravenous, During each 6 week cycle: 3 times/week during weeks 1 and 3, Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years |
| Part 2-Arm A: BMS-982470 (weekly x 4) + BMS-936558 | EXPERIMENTAL | Cohort Expansion BMS-982470 (dose selected in Part 1) Solution, Intravenous, During each 6 week cycle: weekly x 4 (i.e during weeks 1 through 4), Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years |
| Name | Type | Description |
|---|---|---|
| Denenicokin | BIOLOGICAL | - |
| Nivolumab | BIOLOGICAL | - |
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * All subjects will have locally advanced or metastatic solid tumors * For Part 2 (Cohort Expansion): * Tumor types will be restricted to clear cell renal cell carcinoma (cc...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
Denenicokin is an investigational monoclonal antibody being studied for the treatment of neoplasms by site, a category of solid tumors. It is in Phase 1 clinical development for oncology indications. The drug is not yet approved and remains under investigation.
Denenicokin is a monoclonal antibody that targets the IL-21 receptor pathway. It is designed to modulate immune responses in the context of cancer therapy. The specific molecular target is IL-21, a cytokine involved in immune cell regulation.
Denenicokin is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
Denenicokin is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not received FDA approval and is still being evaluated for safety and tolerability in patients with solid tumors.
Denenicokin has been studied in one completed Phase 1 clinical trial, NCT01629758, titled "Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors." The trial enrolled 33 participants in the United States and evaluated the drug in patients with neoplasms by site.
Denenicokin is a monoclonal antibody that targets IL-21, but it is not the same as IL-21 itself. IL-21 is a cytokine, while Denenicokin is an antibody designed to interact with the IL-21 pathway. The drug is being studied for its potential role in cancer treatment.